Clinical trials: Metastatic Neoplasm
Melanoma
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
The objective of this study is to evaluate the clinical activity of the GSK2132231A immunotherapeutic in patients with MAGE-A3 positive unresectable metastatic melanoma presenting with the predictive gene signature.
- Trial name
- PREDICT (NCT00942162)
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 63 sites in United States, France and 6 more
- Volunteers
- 125 people
- Sponsor
- GlaxoSmithKline
Adenocarcinoma
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
This is a single-agent, open label, one-arm phase 2 pilot study of avelumab in patients with advanced or metastatic adenocarcinoma of the small intestine.
- Trial name
- NCT03000179
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Prostate Cancer, Metastasis
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
This multi-center, phase II trial will be conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT)…
- Conditions
- Prostate Cancer, Metastasis, Toxicity Due to Radiotherapy, Circulating Tumour DNA
- Trial name
- TRAP (NCT03644303)
- Testing
- SBRT + ADT
- Where
- 7 sites in United Kingdom
- Volunteers
- 86 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Neoplasm, Unknown Primary
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
We will evaluate the feasibility, toxicity, and effectiveness of combination chemotherapy (paclitaxel/carboplatin)plus combination targeted therapy (bevacizumab/erlotinib)in the first line treatment of patients with carcinoma of…
- Trial name
- NCT00360360
- Testing
- paclitaxel, carboplatin, bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Esophageal Cancer, Gastric Cancer
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
There is no clear standard of care for metastatic stomach or esophageal cancer in the United States. The purpose of this research study is to determine the differences between two regimens of chemotherapy; Arm A: PCA (Cisplatin…
- Conditions
- Esophageal Cancer, Gastric Cancer, Stomach Cancer
- Trial name
- NCT00911820
- Testing
- Bevacizumab, Cisplatin, Irinotecan
- Where
- 4 sites in United States
- Volunteers
- 88 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer
Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- PIMABI (NCT00655499)
- Testing
- Panitumumab, Irinotecan hydrochloride, Chromogenic in situ hybridization
- Where
- 9 sites in France
- Volunteers
- 65 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Renal Cell Carcinoma
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC).
- Trial name
- NCT02853344
- Testing
- Pembrolizumab
- Volunteers
- 275 people
- Sponsor
- Merck Sharp & Dohme LLC
ER+ and AR+ Breast Cancer
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+…
- Trial name
- NCT02463032
- Testing
- GTx-024
- Where
- 4 sites in United States
- Volunteers
- 136 people
- Sponsor
- GTx
Non-Small Cell Lung Cancer
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.
- Trial name
- NCT02584634
- Testing
- Avelumab, PF-06463922, Crizotinib
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 43 people
- Sponsor
- Pfizer
Gastric Cancer, Gastroesophageal Junction Cancer
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
- Trial name
- MAHOGANY (NCT04082364)
- Testing
- margetuximab, Retifanlimab, Tebotelimab
- Where
- 73 sites in United States, China and 7 more
- Volunteers
- 82 people
- Sponsor
- MacroGenics
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
This study is designed to evaluate the efficacy of pamiparib in participants with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency…
- Trial name
- NCT03712930
- Testing
- Pamiparib
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- BeiGene
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine (T-DM1) administered by intravenous (IV)…
- Trial name
- NCT00951665
- Testing
- paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
- Trial name
- ALERT-lung (NCT03445000)
- Testing
- Alectinib
- Where
- 19 sites in Belgium, Ireland and 4 more
- Volunteers
- 14 people
- Sponsor
- ETOP IBCSG Partners Foundation
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly (ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants…
- Trial name
- KEYLYNK-010 (NCT03834519)
- Testing
- Pembrolizumab, Olaparib, Abiraterone acetate
- Where
- 193 sites in United States, Argentina and 18 more
- Volunteers
- 793 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
This research study is studying a combination of drugs as a possible treatment for metastatic breast cancer. The interventions involved in this study are: Pembrolizumab Trastuzumab emtansine (also called T-DM1)
- Trial name
- NCT03032107
- Testing
- T-DM1, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Prostate Cancer, Prostate Adenocarcinoma
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Prostate Cancer Recurrent
- Trial name
- NCT03396874
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 1,435 people
- Sponsor
- University of Michigan
Colorectal Cancers
Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for patients with advanced colorectal cancer that no longer responds to standard therapies.
- Trial name
- NCT02046174
- Testing
- RENCA macrobeads
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- The Rogosin Institute
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works in treating patients…
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01157091
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis, immunologic technique
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- City of Hope Medical Center
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver…
- Conditions
- Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT03695250
- Testing
- IDO1 Inhibitor BMS-986205, Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Edward Kim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.